Network Meta-Analysis — Pharmacological T2DM Prevention in Arab Populations
Simulated Case Study
This case study uses simulated data to demonstrate the statistical methodology, analysis workflow, and reporting standards we apply to real client projects. No actual patient or institutional data is represented.
NMA · GRADE · SUCRA · PRISMA 2020
Open Methodology Notice
This network meta-analysis is based entirely on published, peer-reviewed trial data. No unpublished or confidential data was used. The analysis code and PRISMA flow diagram are available on reasonable request.
Project Overview
The Kuwait Institute for Medical Research commissioned a comprehensive network meta-analysis to synthesize evidence on pharmacological interventions for preventing Type 2 Diabetes Mellitus in at-risk adults, with a specific focus on Arab-population data. A systematic search across MEDLINE, Embase, CENTRAL, and CINAHL identified 47 eligible RCTs enrolling 31,420 participants across four intervention nodes: metformin, intensive lifestyle intervention, GLP-1 receptor agonists, and control.
Using the frequentist NMA framework (R: netmeta), we assessed both direct and indirect evidence, tested for network inconsistency (node-splitting and global tests), and generated SUCRA-based treatment rankings for T2DM incidence reduction. GRADE certainty of evidence was evaluated for each comparison-outcome pair. A pre-specified subgroup NMA was conducted for the 11 trials reporting Arab-population data (n = 4,820), confirming consistent direction of effects despite wider confidence intervals.
Key Findings
- ✓47 eligible RCTs identified; 31,420 participants across 4 intervention nodes
- ✓GLP-1 receptor agonists ranked highest for T2DM incidence reduction (SUCRA = 82%)
- ✓Metformin + intensive lifestyle combination superior to either alone (OR = 0.41, 95% CI 0.31–0.54)
- ✓Arab-population subgroup (11 trials, n = 4,820): consistent direction of effects; wider CIs
Analytical Methods
- ▹Systematic search — MEDLINE, Embase, CENTRAL, CINAHL (through December 2023)
- ▹PICOS-based screening — two independent reviewers; κ = 0.87 inter-rater agreement
- ▹Risk of bias — RoB 2.0 for RCTs; ROBINS-I for non-randomized studies
- ▹Pairwise meta-analysis — random-effects (DerSimonian-Laird), I² + τ² heterogeneity
- ▹Network meta-analysis — frequentist consistency model (R: netmeta 2.9, graph-theoretical approach)
- ▹Inconsistency testing — local (node-splitting) and global (design-by-treatment interaction model)
- ▹Treatment rankings — SUCRA scores, P-score, rankogram for T2DM incidence reduction
- ▹GRADE certainty — evaluated per comparison × outcome (downgraded for risk of bias, inconsistency, imprecision)
- ▹Subgroup NMA — baseline BMI strata (< 30 vs ≥ 30 kg/m²); baseline HbA1c strata
- ▹PRISMA-NMA 2020 reporting checklist — full compliance; PROSPERO pre-registration